Request Processed
Your registration request has been processed. We will contact you soon.
Register
First name
Last name
Email
Company
Toggle navigation
Toggle navigation
Login
Register
About
Contact Us
1
2
3
4
5
6
Next ›
Last »
FDA Inspection Authority Provisions In FDORA May Help Make 2023 A Happy New Year For Agency
January 6, 2023
Prevision Policy Clips | Narcan OTC Will Be Reviewed By FDA Advisory Committee: Broader Implications
January 6, 2023
Eylea Pediatric Use: FDA Asks Committee For Closer Look At Proposed Label For Infant Retinopathy; Agency May Want More Post-Treatment Monitoring
January 6, 2023
Advisory Committee Tracker: Another Unusual ODAC Set For February; COVID Vaccines, iPledge REMS Will Also Be Topics Early In 2023
January 5, 2023
Prevision Policy Clips | Seven Years’ War: Fabre-Kramer Submits NDA Amendment For Gepirone Seven Years After Dispute Resolution
January 5, 2023
Prevision Policy Clips | REMS Content & Format Final Guidance From FDA
January 4, 2023
Aduhelm Congressional Report Provides Anticlimactic Coda To FDA Controversy; Clarifying Use Of “Point/Counterpoint” Briefing Document May Be One Outcome
January 3, 2023
CMS New Technology Add-On Payment Applications For FY 2024 Include Five Bispecific Antibodies Among 20 Drug Candidates; Likely Rebound After Small Class Of 2023
January 3, 2023
Prevision Policy Clips | FDA Novel Therapeutics Approvals In 2022
January 3, 2023
Prevision Policy Clips | FDORA Set To Become Law
December 23, 2022
FDORA Clinical Trial Provisions Are Jumping Off Point For FDA Priority Under Califf: Diversity Is Main Political Theme; “Decentralized” And “Seamless” Guidances Will Be Key For Industry
December 22, 2022
“Platform Technologies” Pathway Will Be Important New FDA Tool In 2023; Sen. Burr’s Parting Gifts Include Stripping “Anti-Innovation” Amendments From FDA Year-End Package
December 22, 2022
Prevision Policy Clips | J&J, Perrigo Among Participants In Briefing With HHS Secretary On OTC Pediatric Cold & Flu Medicines
December 22, 2022
Accelerated Approval Reforms In FDORA Follow Senate Blueprint; Highlight of “Drugs & Biologics” Section Of Year-End Bill
December 21, 2022
FDORA Puts Cap On Big Year For FDA: User Fee Riders, PREVENT Pandemic Act Reforms Make Year End Omnibus; “Platform Technologies” Could Be One To Watch
December 21, 2022
Prevision Policy Clips | GSK Jemperli Rectal Cancer Indication Development Plan Will Be Focus Of Unusual ODAC
December 21, 2022
ICER Panel Skeptical Of Astellas’ Novel NK3 For Menopause Symptoms; Lack Of Peer Reviewed Data Raises Concerns
December 20, 2022
Prevision Policy Clips | FDA Reforms Ready To Move In Lame Duck: “FDORA”
December 20, 2022
FDA Gene Editing Safety Workshop: Targeted Approaches To Screen For Off-Target Effects?
December 19, 2022
Prevision Policy Clips | Madrigal Pharma To Pursue Accelerated Approval For NASH Drug In First Half Of 2023
December 19, 2022
Cytokinetics OM For Heart Failure Has Uncertain Future: Large Heart Failure Trial Is Not “Substantial Evidence” On Its Own, FDA Committee Agrees
December 16, 2022
Prevision Policy Clips | FDA’s VRBPAC To Meet Jan. 26 To Discuss “Future Vaccination Regimens” For COVID, Still Virtual
December 16, 2022
Sentinel Pregnancy Data Work Under PDUFA VII May Be Key Step In Moving FDA Active Surveillance System Beyond Supporting Role; EHR Integration Is Longer-Term Opportunity
December 15, 2022
OCE’s “Project Renewal” Concludes First Label Update – After Four Years: Genentech Xeloda Has Eight New And Revised Indications
December 15, 2022
Prevision Policy Clips | CMS Delays Initial Decision On Updating Beta Amyloid PET Scan Coverage Policy
December 15, 2022
1
2
3
4
5
6
Next ›
Last »